

10/616,888

=> file caplus

FILE 'CAPLUS' ENTERED AT 13:45:38 ON 21 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Sep 2005 VOL 143 ISS 13


FILE LAST UPDATED: 20 Sep 2005 (20050920/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 232 SEA FILE=REGISTRY SSS FUL L1

L4 5 SEA FILE=CAPLUS L3

=> d l4 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:523447 CAPLUS

DOCUMENT NUMBER: 143:59964


TITLE: Preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy

INVENTOR(S): Deshpande, Prasad Keshav; Sindkhedkar, Milind Dattatraya; Phansalkar, Mahesh Shriram; Yeole, Ravindra Dattatrya; Gupte, Shrikant Vinayak; Chugh, Yati; Shetty, Nitin; Bhagwat, Sachin Subhash; De


10/616,888

PATENT ASSIGNEE(S): Souza, Noel John; Patel, Mahesh Vithalbhai
SOURCE: India
PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054234	A2	20050616	WO 2004-IN276	20040908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005143421	A1	20050630	US 2004-935708	20040907
PRIORITY APPLN. INFO.:			IN 2003-MU924	A 20030908
OTHER SOURCE(S):	MARPAT 143:59964			
GI				



I



II

AB The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenyloxazolidinone derivs. (shown as I; variables defined below; e.g. (S)-N-[[3-[4-(4-cyanomethyl-4-hydroxypiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide (shown as II)), processes for making compds. as well as antimicrobial compns. containing said derivs. as active ingredients and methods of treating bacterial infections with the said derivs. MIC ($\mu\text{g/mL}$) and/or ED50 (mg/kg) values are tabulated for 5 types of bacteria. For I: $m = 0-1$ and $n = 1-3$; $X = -\text{CN}$, $-\text{OH}$, or halogen; $Y = \text{H}$ (with the proviso that when Y is H , X is OH , F or CN), (un)substituted C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heterocyclylamino, heterocyclylcarbonyl, cyano, halogen, (un)substituted

amino, (un)substituted hydrazino; or X and Y together form a 3-membered carbocyclic ring or heterocyclic ring containing a hetero atom = O or S or X and Y together form an (un)substituted, (un)saturated 3 to 7 membered heterocyclic ring having 1-4 hetero atoms = N, O, S or includes the S atom of groups like sulfinyl or sulfonyl as a part of heterocyclic ring or X and Y together form O:. A, B = H, C1-C6 alkyl, or halogen; R2, R3 = H or halogen. R4 = C1-C6 alkylsulfonyloxy, alkylsulfonyloxyacetamido, (un)substituted aminosulfonyloxy, alkyloxysulfonyloxy, arylsulfonyloxy, (un)substituted amino, azido, aminonitrilo, isocyanato, formamido, N-hydroxyformamido, substituted C1-C6 alkanoyloxy, (un)substituted C1-C6 alkylamido, (un)substituted C1-C6 alkylthiocarbonylamido, C1-C6 alkylsulfonamido; substituted arylsulfonamido, (un)substituted alkylcarbamato, (un)substituted ureido, (un)substituted five to six membered heterocyclyl ring, (un)substituted five to six membered heteroaryl ring, (un)substituted heteroaryloxy, (un)substituted heteroarylamino, or mercapto substituted by C1-C6 alkyl group; addnl. details including provisos are given in the claims. Methods of preparation are claimed and .apprx.180 example preps. are included. For example, 51 % II was prepared by reacting (S)-N-[[3-[4-(1-oxa-6-azaspiro[2.5]octan-6-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide with KCN in MeOH/DMF (1:5) at 25° for 14 h.

IT 853795-09-2P, (S)-N-[[3-[4-(4-Fluoro-4-cyanomethylpiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide

853795-11-6P, (S)-N-[[3-[4-(4-Cyanomethyl-4-hydroxypiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide

853795-83-2P, (S)-N-[[3-[4-[4-(1,1-Dicyanomethyl)-4-cyanopiperidin-1-yl]-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide

853795-88-7P, N-[[[(S)-3-[4-[4-[1-(Pyridin-3-yl)-1-cyanomethyl]-4-cyanopiperidin-1-yl]-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)

RN 853795-09-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-4-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853795-11-6 CAPLUS

10/616,888

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-4-hydroxy-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853795-83-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-cyano-4-(dicyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853795-88-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-cyano-4-(cyano-3-pyridinylmethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648909-88-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-89-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 853794-82-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:372882 CAPLUS

DOCUMENT NUMBER: 140:391269

TITLE: Preparation of methylidene oxazolidinone compounds as antimicrobial agents and preparation method thereof
INVENTOR(S): Koh, Hun Yeong; Cho, Yong Seo; Pae, Ae Nim; Cha, Joo Hwan; Kim, Hye Yeon; Lee, Jae Seok; Kim, Hak Soo; Kim, Sanghee

PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea


SOURCE: U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

10/616,888

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004087633	A1	20040506	US 2003-694843	20031029
PRIORITY APPLN. INFO.:			KR 2002-66268	A 20021029
OTHER SOURCE(S):		CASREACT 140:391269; MARPAT 140:391269		
GI				



AB 3-[4-(3-Methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone compds. represented by formula (I) or pharmaceutically acceptable salt thereof (R1 and R2 independently represent H, cyano, alkyl, halogen, acetoxy, ethoxycarbonyl, hydroxy, hydroxyimino, methoxyimino, aminoethyl, or a unsatd. 5-membered heterocyclic substituent containing one or more hetero atoms selected from the group consisting of O, N and S; n represents an integer 1 or 2), showing superior antimicrobial activities against gram-pos. germs including resistant strains such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococcus, are prepared Also disclosed is a preparation method thereof. These compds. showing superior antimicrobial activities against gram-pos. germs including resistant strains such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococcus. For example, N-[[[(5S)-3-[3-fluoro-4-[4-(cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide showed min. inhibitory concentration of 0.5 µg/mL against vancomycin-resistant Staphylococcus pyogenes C6487 vs. 2 and >32 µg/mL for linezolid and vancomycin, resp.


IT 596136-34-4P, N-[[[(5S)-3-[3-Fluoro-4-(4-cyanomethylidenepiperidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 596136-34-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/616,888



IT 685570-69-8P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-hydroxybutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 685570-69-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-4-hydroxybutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 648919-28-2P, N-[[[(5S)-3-[3-Fluoro-4-[4-(cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide 648919-57-7P,


N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyanoethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 648919-89-5P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-(dicyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 648919-97-5P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-(1-ethoxycarbonyl-1-cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-68-7P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-2-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-70-1P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-4-(methanesulfonyloxy)butylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-73-4P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-aminobutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide 685571-00-0P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-2-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-01-1P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-ethoxycarbonyl-1-cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-02-2P,
 N-[[[(5S)-3-[3-Fluoro-4-(4-cyanomethylidenepiperidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-10-2P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyanoethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-20-4P,
 N-[[[(5S)-3-[3-Fluoro-4-[4-(cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 648919-28-2 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

10/616,888


Absolute stereochemistry.



RN 648919-89-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-97-5 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 685570-68-7 CAPLUS

CN Propanoic acid, 3-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-3-cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 685570-70-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-[1-cyano-4-[(methylsulfonyl)oxy]butylidene]-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN(C)C(=O)[C@H]1CC[C@@H](c2ccc(F)c(N3CCCC3C=C4C(=O)S[C@@H]4C5=CC=CC=C5C(=O)SC6C7=CC=CC=C7C(=O)OC6)cc2)C1


CN	Ethanethioamide, N-[[[(5S)-3-[4-[4-(4-amino-1-cyanobutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)	(CA
----	---	-----

NC(=O)CSC1OC(=O)N1c2ccc(F)cc2N3CCCCC3C(=O)C#N

CN Propanoic acid, 3-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-3-cyano-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 685571-01-1 CAPLUS

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685571-02-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 685571-10-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 685571-20-4 CAPLUS

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(cyanomethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/616,888




IT 685570-71-2P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-azidobutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 685570-71-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(4-azido-1-cyanobutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 685570-72-3

10/616,888


RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of 3-[4-(3-methylidenepiperidin-1-yl or
4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as
antimicrobial agents)

RN 685570-72-3 CAPLUS


CN Acetamide, N-[[[(5S)-3-[4-[4-[1-cyano-2-[(methylsulfonyl)oxy]butylidene]-1-
piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:60503 CAPLUS

DOCUMENT NUMBER: 140:128407

TITLE: Preparation of (piperidinophenyl)oxazolidinones
targeting multiple ribonucleoprotein sites as
antibacterial agents


INVENTOR(S): Patel, Mahesh V.; Deshpande, Prasad K.; Sindkhedkar,
Milind D.; Gupte, Shrikant V.; Chugh, Yati; Shetty,
Nitin; Shukla, Milind C.; Yeole, Ravindra D.; De
Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 156 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007489	A2	20040122	WO 2003-IN238	20030710
WO 2004007489	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2492194 AA 20040122 CA 2003-2492194 20030710 EP 1565461 A2 20050824 EP 2003-753912 20030710 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK PRIORITY APPLN. INFO.: US 2002-395164P P 20020711 WO 2003-IN238 W 20030710 OTHER SOURCE(S): MARPAT 140:128407 GI				



AB Title compds. I [wherein R1 = H, (un)substituted (cyclo)alkyl, (un)substituted alkanoyl, arylmercapto, heterocyclylthiocarbonyl, etc.; R2, R3 = H, halogen; R4 = alkylsulfonyloxy, (un)substituted alkylthiocarbonylamino, (un)substituted ureido, carbamato, etc.; A, B = independently selected from H, alkyl, CO2Et, halogen; and salts or solvates thereof] were prepared as antibacterial agents. For example, reaction of (S)-N-[3-[4-(4-cyanomethylidenepiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]amine with carbon disulfide (69%), followed by addition of sodium methoxide, gave II in 77% yield. II showed 1.56-6.25 µg/mL (MIC) against linezolid resistant strains, such as *S. aureus* MRSA-32, *S. pneumoniae* SPN744 and *E. faecium* 367, 0.2 µg/mL (MIC) against linezolid sensitive strains, such as *S. aureus* MRSA-32 and *S. pneumoniae* 49619, 1.56 (MPC) for the treatment of *E. faecalis* 416 infection, and etc. 3D quant. structure activity relationship (3D-QSAR) showed that the steric contributions of I are over one and half times more

10/616,888

than the electrostatic contributions, compared to literature compds. Thus, I and their pharmaceutical compds. targeting multiple ribonucleoprotein sites are useful as antimicrobial agents for treating bacterial infections.


IT 596136-34-4P 648909-90-4P 648918-89-2P
648918-90-5P 648918-93-8P 648918-97-2P
648919-00-0P 648919-01-1P 648919-02-2P
648919-05-5P 648919-10-2P 648919-12-4P
648919-25-9P 648919-38-4P 648919-51-1P
648919-57-7P 648919-65-7P 648919-72-6P
648919-80-6P 648919-82-8P 648919-83-9P
648919-85-1P 648919-88-4P 648919-89-5P
648919-90-8P 648919-93-1P 648919-94-2P
648919-95-3P 648919-97-5P 648919-99-7P
648920-05-2P 648920-07-4P 648920-14-3P
648920-21-2P 648920-22-3P 648920-25-6P
648920-26-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)

RN 596136-34-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-90-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-3-fluoro-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/616,888



RN 648918-89-2 CAPLUS

CN Acetonitrile, [1-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]phenyl]-4-piperidinylidene]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648918-90-5 CAPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[[[(5R)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648918-93-8 CAPLUS

CN Acetonitrile, [1-[2-fluoro-4-[(5S)-5-(isocyanatomethyl)-2-oxo-3-oxazolidinyl]phenyl]-4-piperidinylidene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648918-97-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648919-00-0 CAPLUS

CN Acetonitrile, [1-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyldene]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-01-1 CAPLUS

CN Acetonitrile, [1-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyldene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:60502 CAPLUS

DOCUMENT NUMBER: 140:128406

TITLE: Preparation of (piperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages

INVENTOR(S): Chugh, Yati; Shetty, Nitin; Deshpande, Prasad K.; Sindkhedkar, Milind D.; Jafri, Mohammad A.; Yeole, Ravindra D.; Shukla, Milind C.; Gupte, Shrikant V.; Patel, Mahesh V.; De Souza, Noel J.

PATENT ASSIGNEE(S): India

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007488	A2	20040122	WO 2003-IN237	20030710
WO 2004007488	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492743	AA	20040122	CA 2003-2492743	20030710
US 2004063954	A1	20040401	US 2003-616888	20030710
EP 1546140	A2	20050629	EP 2003-758645	20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004235900	A1	20041125	US 2003-475735	20031023
PRIORITY APPLN. INFO.:			US 2002-395164P	P 20020711
			IN 2003-MU392	A 20030421
			WO 2003-IN237	W 20030710

OTHER SOURCE(S): CASREACT 140:128406; MARPAT 140:128406

GI



AB Title compds. I•A [wherein R1 = H, (un)substituted alkyl, CO₂H, CN; R2, R3 = H, F; R4 = (un)substituted alkyl, alkoxy; D = H, alkyl, F; A = absent or a complex forming agent, organic base, amino acid] were prepared as antimicrobial agents. For example, reduction of N-[[[(S)-3-[4-(4-cyanomethylidenepiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]acetamide with 10% Pd/C afforded II in 89% yield. II showed 1.0-2.0 µg/mL (MIC) against *S. aureus* MRSA-32, *E. faecalis* ATCC 29212 and *S. pneumoniae* ATCC 49619, good pharmacokinetic values, such as a higher 12-h blood level and a longer half-life than the control, and no toxicity. Thus, I and their pharmaceutical compds. have an improved pharmacokinetic profile and no toxicity in use as antimicrobial agents for preventing and treating bacterial infections in once-a-day doses.

IT 648910-08-1P 648910-09-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(complex with 3-HP-β-CD; preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages)

RN 648910-08-1 CAPLUS

CN β-Cyclodextrin, 6A-O-(3-hydroxypropyl)-, compd. with N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (6:5) (9CI) (CA INDEX NAME)


CM 1

CRN 648909-91-5

CMF C19 H23 F N4 O3

Absolute stereochemistry.


10/616,888



CM 2

CRN 156969-96-9

CMF C45 H76 O36



RN 648910-09-2 CAPLUS

CN β -Cyclodextrin, 6A-O-(3-hydroxypropyl)-, compd. with
N-[[[5S]-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 648909-91-5

10/616,888

CMF C19 H23 F N4 O3


Absolute stereochemistry.



CM 2

CRN 156969-96-9

CMF C45 H76 O36



IT 648909-87-9P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial


10/616,888

agents with improved pharmacokinetic profile and safety advantages)

RN 648909-87-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 648909-91-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages)

RN 648909-91-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/616,888

IT 648909-85-7P 648909-89-1P 648909-92-6P
648909-94-8P 648909-96-0P 648909-97-1P
648909-98-2P 648909-99-3P 648910-00-3P
648910-01-4P 648910-02-5P 648910-03-6P
648910-04-7P 648910-05-8P 648910-06-9P
648910-07-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial
agents with improved pharmacokinetic profile and safety advantages)

RN 648909-85-7 CAPLUS

CN Formamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]phenyl]-2-oxo-5-
oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-89-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-3-fluoro-1-piperidinyl]phenyl]-2-
oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648909-92-6 CAPLUS

CN Propanamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-94-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648909-96-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-97-1 CAPLUS

CN Carbamic acid, [[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648909-98-2 CAPLUS

CN Carbamic acid, [[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-99-3 CAPLUS

CN Carbamic acid, [[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648910-00-3 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-3-methyl-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648910-01-4 CAPLUS

CN Carbamic acid, [[[(5S)-3-[4-[4-(cyanomethyl)-3-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648910-02-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648910-03-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanopropyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648910-04-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanobutyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648910-05-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648910-06-9 CAPLUS

CN 4-Piperidineacetic acid, 1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-α-cyano- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 648910-07-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

CC(=O)N[C@H]1CC[C@@H](C2=CC=C(C=C2)C(F)=CC3=CC=C(C=C3)N3CCCC(C3)C(C4=CC=CC=C4C(=O)N)C5=CC=CC=C5C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C9=CC=CC=C9C10=CC=CC=C10)C1

RL: RCT (Reactant); RACT (Reactant or reagent)

RN 596136-34-4 CAPLUS


Absolute stereochemistry.



CN Formamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

10/616,888


Absolute stereochemistry.



RN 648909-88-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-90-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-3-fluoro-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/616,888



RN 648909-93-7 CAPLUS

CN Propanamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648909-95-9 CAPLUS

CN Acetamide, 2,2-dichloro-N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648919-14-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-22-6 CAPLUS

CN Carbamic acid, [[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648919-41-9 CAPLUS

CN Carbamic acid, [[(5S)-3-[4-[4-(cyanomethylene)-3-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 2-methylpropyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 648919-46-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-3-methyl-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/616,888



RN 648919-57-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-72-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanopropylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648919-89-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 653597-30-9 CAPLUS

CN Carbamic acid, [[[5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 653597-32-1 CAPLUS

CN Carbamic acid, [[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 653597-37-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanobutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 653597-38-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-2-hydroxyethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 653597-47-8 CAPLUS


CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/616,888



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:442768 CAPLUS
DOCUMENT NUMBER: 139:245931
TITLE: Synthesis and in vitro activity of new
methylenepiperidinyloxazolidinone and methylenepyrrolidinyl
oxazolidinone antibacterial agents
AUTHOR(S): Kim, Hye Yeon; Lee, Jae Seok; Cha, Joo Hwan; Pae, Ae
Nim; Cho, Yong Seo; Chang, Moon Ho; Koh, Hun Yeong
CORPORATE SOURCE: Biochemicals Research Center, Korea Institute of
Science and Technology, Cheongryang, Seoul, 130-650,
S. Korea
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),
13(13), 2227-2230
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:245931
GI



AB A series of substituted methylenepiperidinyloxazolidinones I (R1 = H, Me, CN; R2 = CN, CO2Et, COMe, CHO, etc.) have been prepared and evaluated for antibacterial activity against several gram-pos. strains, including the resistant strains of Staphylococcus and Enterococcus, such as MRSA, CRSA, MSSA and VRE. Some of them showed comparable or superior in vitro activities (MIC) to vancomycin.
IT 596136-34-4P


10/616,888

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(synthesis and in vitro activity of [(methylenepiperidinyl) or
(methylenepyrrolidinyl)fluorophenyl]oxazolidinone antibacterial agents)

RN 596136-34-4 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-
fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall

FILE 'USPATFULL' ENTERED AT 13:46:36 ON 21 SEP 2005


CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:46:36 ON 21 SEP 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1 STR



10/616,888

Structure attributes must be viewed using STN Express query preparation.

L3 232 SEA FILE=REGISTRY SSS FUL L1
L5 4 SEA L3

=> d 15 1-4 ibib abs hitstr

L5 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2005:165996 USPATFULL

TITLE: Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy

INVENTOR(S): Deshpande, Prasad Keshav, Maharashtra State, INDIA
Sindkhedkar, Milind Dattatraya, Maharashtra State, INDIA

Phansalkar, Mahesh Shriram, Maharashtra State, INDIA

Yeole, Ravindra Dattatraya, Maharashtra State, INDIA

Gupte, Shrikant Vinayak, Maharashtra State, INDIA

Chugh, Yati, Maharashtra State, INDIA

Shetty, Nitin, Maharashtra State, INDIA

Bhagwat, Sachin Subhash, Maharashtra State, INDIA

Shukla, Milind Chintaman, Maharashtra State, INDIA

De Souza, Noel John, Maharashtra State, INDIA

Patel, Mahesh Vithalbhair, Maharashtra State, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143421	A1	20050630
APPLICATION INFO.:	US 2004-935708	A1	20040907 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2003-9242003	20030908
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Janet I. Cord, Ladas & Parry, 26 West 61 Street, New York, NY, 10023, US	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4940	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides agents having antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel substituted piperidino phenyloxazolidinone derivatives, processes for making compounds as well as antimicrobial compositions containing said derivatives as active ingredients and methods of treating bacterial infections with the said derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 853795-09-2P, (S)-N-[[3-[4-(4-Fluoro-4-cyanomethylpiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide
853795-11-6P, (S)-N-[[3-[4-(4-Cyanomethyl-4-hydroxypiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide
853795-83-2P, (S)-N-[[3-[4-(4-(1,1-Dicyanomethyl)-4-cyanopiperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide 853795-88-7P, N-[[3-(S)-3-[4-[4-[1-(Pyridin-3-yl)-1-cyanomethyl]-4-cyanopiperidin-1-yl]-3-fluorophenyl]-2-oxooxazolidin-5-yl]methyl]ethanamide


(drug candidate; preparation of 3-(4-piperidinophenyl)oxazolidinones having antibacterial activity with improved in vivo efficacy)

RN 853795-09-2 USPATFULL

10/616,888

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-4-fluoro-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853795-11-6 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethyl)-4-hydroxy-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 853795-83-2 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-cyano-4-(dicyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/616,888


Absolute stereochemistry.



RN 853794-82-8 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylene)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:300031 USPATFULL

TITLE: Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages

INVENTOR(S): Chugh, Yati, Chikalthana Aurangabad, INDIA
Shetty, Nitin, Chikalthana Aurangabad, INDIA
Deshpande, Prasad K, Chikalthana Aurangabad, INDIA
Sindkhedkar, Milind D, Chikalthana Aurangabad, INDIA
Jafri, Mohammad A, Chikalthana Aurangabad, INDIA

10/616,888

Yeole, Ravinda D, Chikalthana Aurangabad, INDIA
Shukla, Milind C, Chikalthana Aurangabad, INDIA
Gupte, Shirikant V, Chikalthana Aurangabad, INDIA
Patel, Mahesh V, Chikalthana Aurangabad, INDIA
De Souza, Noel J, Chikalthana Aurangabad, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004235900	A1	20041125
APPLICATION INFO.:	US 2003-475735	A1	20031023 (10)
	WO 2003-IN237		20030710

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60395164	20020711
	IN 2003-3922003	20030421
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1298	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides agents having high antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel cyanoalkylpiperidinophenyl oxazolidinone derivatives having antimicrobial activity, favourable pharmacokinetic and safety profiles, processes for making the compounds, as well as antimicrobial compositions containing said derivatives as active ingredients and methods of treating microbial infections with the said derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648910-08-1P 648910-09-2P

(complex with 3-HP- β -CD; preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages)

RN 648910-08-1 USPATFULL

CN β -Cyclodextrin, 6A-O-(3-hydroxypropyl)-, compd. with
N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (6:5) (9CI) (CA INDEX NAME)

CM 1


CRN 648909-91-5

CMF C19 H23 F N4 O3

Absolute stereochemistry.

CC(=O)N[C@@H]1C[C@H](C(=O)N2C(=O)C=C[C@H]2c3ccc(cc3N4CCCCC4C5CCN5)cc(F)c3)C1

CRN 156969-96-9
CMF C45 H76 O36
CDES 6:B-CYCLODEXTRIN



CN β-Cyclodextrin, 6A-O-(3-hydroxypropyl)-, compd. with
N-[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide (2:1) (9CI) (CA INDEX NAME)


10/616,888

CM 1

CRN 648909-91-5

CMF C19 H23 F N4 O3

Absolute stereochemistry.




CM 2


CRN 156969-96-9

CMF C45 H76 O36

CDES 6:B-CYCLODEXTRIN




10/616,888



RN 653597-47-8 USPATFULL

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinyldene]cyano- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:114787 USPATFULL

TITLE: Methylidene oxazolidinone compound and preparation method thereof

INVENTOR(S): Koh, Hun Yeong, Seoul, KOREA, REPUBLIC OF
Cho, Yong Seo, Seoul, KOREA, REPUBLIC OF
Pae, Ae Nim, Seoul, KOREA, REPUBLIC OF
Cha, Joo Hwan, Seoul, KOREA, REPUBLIC OF
Kim, Hye Yeon, Seoul, KOREA, REPUBLIC OF
Lee, Jae Seok, Gyeonggi-Do, KOREA, REPUBLIC OF
Kim, Hak Soo, Seoul, KOREA, REPUBLIC OF

10/616,888

PATENT ASSIGNEE(S): Kim, Sanghee, Seoul, KOREA, REPUBLIC OF
Korea Institute of Science and Technology, Seoul,
KOREA, REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004087633	A1	20040506
APPLICATION INFO.:	US 2003-694843	A1	20031029 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	KR 2002-66268	20021029
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 1650 TYSONS BOULEVARD, SUITE 300, MCLEAN, VA, 22102	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1175	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A methylidene oxazolidinone compound represented by formula (1) or a pharmaceutically acceptable salt thereof, and a preparation method thereof, showing superior antimicrobial activities against gram-positive germs including resistant strains such as methicillic-resistant staphylococcus aureus and vancomycin-resistant enterococcus: ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 596136-34-4P, N-[[[(5S)-3-[3-Fluoro-4-(4-cyanomethylidenepiperidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (intermediate; preparation of 3-[4-(3-methylidenepiperidin-1-yl or 4-methylidenepyrrolidin-1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 596136-34-4 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 685570-69-8P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-hydroxybutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide


10/616,888

(preparation of 3-[4-(3-methylidenepiperidin-1-yl or
4-methylidenepyrrolidin-
1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)

RN 685570-69-8 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyano-4-hydroxybutylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 648919-28-2P, N-[[[(5S)-3-[3-Fluoro-4-[4-(cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide 648919-57-7P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyanoethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 648919-89-5P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(dicyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 648919-97-5P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(1-ethoxycarbonyl-1-cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-68-7P
, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-2-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
685570-70-1P, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-4-(methanesulfonyloxy)butylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 685570-73-4P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyano-4-aminobutylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide 685571-00-0P
, N-[[[(5S)-3-[3-Fluoro-4-[4-[1-cyano-2-(ethoxycarbonyl)ethylidene]piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride
685571-01-1P, N-[[[(5S)-3-[3-Fluoro-4-[4-(1-ethoxycarbonyl-1-cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-02-2P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(cyanomethylidenepiperidin-1-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-10-2P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(1-cyanoethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride 685571-20-4P,
N-[[[(5S)-3-[3-Fluoro-4-[4-(cyanomethylidene)piperidin-1-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide hydrochloride
(preparation of 3-[4-(3-methylidenepiperidin-1-yl or

4-methylidenepyrrolidin-

1-yl)phenyl]-2-oxazolidinone derivs. as antimicrobial agents)


RN 648919-28-2 USPATFULL

CN Ethanethioamide, N-[[[(5S)-3-[4-[4-(cyanomethylene)-1-piperidinyl]-3-

10/616,888

fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 648919-57-7 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-(1-cyanoethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 648919-89-5 USPATFULL

CN Acetamide, N-[[[(5S)-3-[4-[4-(dicyanomethylidene)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/616,888



RN 648919-97-5 USPATFULL

CN Acetic acid, [1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]cyano-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685570-68-7 USPATFULL

CN Propanoic acid, 3-[1-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-4-piperidinylidene]-3-cyano-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:83498 USPATFULL

TITLE: Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites

INVENTOR(S): Patel, Mahesh V., Chikalthana Aurangabad, INDIA
 Deshpande, Prasad K., Chikalthana Aurangabad, INDIA
 Sindkhedkar, Milind D., Chikalthana Aurangabad, INDIA
 Gupte, Shrikant V., Chikalthana Aurangabad, INDIA
 Chugh, Yati, Chikalthana Aurangabad, INDIA
 Shetty, Nitin, Chikalthana Aurangabad, INDIA
 Shukla, Milind C., Chikalthana Aurangabad, INDIA
 Yeole, Ravindra D., Chikalthana Aurangabad, INDIA
 De Souza, Noel J., Chikalthana Aurangabad, INDIA

PATENT ASSIGNEE(S): WOCKHARDT LIMITED (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004063954	A1	20040401
APPLICATION INFO.:	US 2003-616888	A1	20030710 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2003-3922003	20030421
	US 2002-395164P	20020711 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4677	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides agents having high antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel cyano-(substituted)-methylenepiperidinophenyl oxazolidinone derivatives, processes for making the compounds, as well as antimicrobial compositions containing said derivatives as active ingredients and methods of treating bacterial infections with the said derivatives.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 648910-08-1P 648910-09-2P
 (complex with 3-HP- β -CD; preparation of (cyanoalkylpiperidinophenyl)oxazolidinones as antimicrobial agents with improved pharmacokinetic profile and safety advantages)

RN 648910-08-1 USPATFULL

CN β -Cyclodextrin, 6A-O-(3-hydroxypropyl)-, compd. with
 N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (6:5) (9CI) (CA INDEX NAME)


10/616,888

CM 1

CRN 648909-91-5

CMF C19 H23 F N4 O3

Absolute stereochemistry.




CM 2

CRN 156969-96-9

CMF C45 H76 O36

CDES 6:B-CYCLODEXTRIN



10/616,888

RN 648910-09-2 USPATFULL


CN β -Cyclodextrin, 6A-O-(3-hydroxypropyl)-, compd. with
N-[[[(5S)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]acetamide (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 648909-91-5

CMF C19 H23 F N4 O3

Absolute stereochemistry.



CM 2

CRN 156969-96-9

CMF C45 H76 O36

CDES 6:B-CYCLODEXTRIN